SCHEMBL4004647

SCHEMBL4004647

CCOC(=O)C(C(=O)OCC)C(=O)C(C)(CC1CCCCC1)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.42
SLC6A3 Q01959 5/20 0.42
SLC6A2 P23975 4/20 0.42
SLC6A4 P31645 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPT P10636 1/20 0.42
CHRM2 P08172 8/20 0.41
CHRM1 P11229 8/20 0.41
CHRM4 P08173 7/20 0.41
CHRM3 P20309 7/20 0.41
NPSR1 Q6W5P4 2/20 0.40
PLA2G1B P04054 1/20 0.40
ATG4B Q9Y4P1 1/20 0.40
CYP2C19 P33261 2/20 0.39
KCNH2 Q12809 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4007594 0.99 SLC6A2 (0.43) TSHRL3MBTL1SLC6A3SLC6A2SLC6A4
SCHEMBL4000097 0.96 SLC6A2 (0.40) TSHRL3MBTL1SLC6A3SLC6A2SLC6A4
SCHEMBL3998876 0.87 TSHR (0.42) TSHRL3MBTL1SLC6A3SLC6A2SLC6A4
SCHEMBL4006317 0.80 KEAP1 (0.46) CHRM2CHRM1CHRM4CHRM3CYP2C19
SCHEMBL4006253 0.78 KEAP1 (0.47) CHRM2CHRM1CHRM4CHRM3CYP2C19
SCHEMBL4006330 0.78 KCNN4 (0.46) SLC6A3SLC6A2ALDH1A1CHRM2CHRM1
SCHEMBL4000449 0.77 PIN1 (0.43) TSHRALDH1A1CHRM2CHRM1CHRM4
SCHEMBL4885111 0.76 ALDH1A1 (0.50) TSHRSLC6A3SLC6A2ALDH1A1MAPT
SCHEMBL4123392 0.76 MAPT (0.42) TSHRL3MBTL1MAPTKCNH2OPRM1
SCHEMBL4127273 0.76 PIN1 (0.42) TSHRL3MBTL1ALDH1A1CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538105-B2 Anti-infective agents ABBOTT LABORATORIES (US) 2009-05-26 US disclosed
US-20080193413-A1 Anti-Infective Agents ABBOTT LABORATORIES (US) 2008-08-14 US disclosed
US-7378414-B2 Viricides for infections caused by an RNA-containing virus; enzyme inhibitors for a hepatitis C virus (HCV) polymerase; inhibiting HCV viral replication; liver cirrhosis; e. g., 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1,1-dipropyl-2(1H)-naphthalenone ABBOTT LABORATORIES (US) 2008-05-27 US disclosed
US-20050107364-A1 Viricides for infections caused by an RNA-containing virus; enzyme inhibitors for a hepatitis C virus (HCV) polymerase; inhibiting HCV viral replication; liver cirrhosis; e. g., 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1,1-dipropyl-2(1H)-naphthalenone ABBVIE INC. 2005-05-19 US disclosed
WO-2005019191-A2 1, 1-DIOXIDO-4H-1,2,4-BENZOTHIADIAZINE DERIVATE UND VERWANDTE VERBINDUNGEN ALS INHIBITOREN DER HCV POLYMERASE ZUR BEHANDLUNG VON HEPATITIS C ABBOTT LABORATORIES (US) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080193413-A1 Anti-Infective Agents POLI, RPL5, POLRMT TSHR 4235/4885L3MBTL1 3674/4885SLC6A3 4436/4885
US-20050107364-A1 Viricides for infections caused by an RNA-containing virus; enzyme inhibitors for a hepatitis C virus (HCV) polymerase; inhibiting HCV viral replication; liver cirrhosis; e. g., 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1,1-dipropyl-2(1H)-naphthalenone POLRMT, RNASE1, RNGTT TSHR 4620/4885L3MBTL1 1432/4885SLC6A3 4271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.